 | • レポートコード：MRC2303M130 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界の疼痛管理市場規模が、今年末までに79,448.93百万ドルとなり、予測期間中に年平均成長率7.39%で拡大し、120,781.07百万ドルに達すると予測されています。本書は、疼痛管理の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疼痛管理BYモード別（治療薬、装置）分析、用途別（神経因性疼痛、がん性疼痛、顔面疼痛・片頭痛、筋骨格痛）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、Abbott Laboratories、Baxter International Inc. (Avante Health Solutions)、Becton, Dickinson and Company、Boston Scientific Corporation、Fresenius SE & Co. KGaA、Johnson & Johnson、Medtronic PLC、Novartis AG、Endo International PLC、Pfizer Inc.など、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の疼痛管理市場規模：疼痛管理BYモード別 - 治療薬における市場規模 - 装置における市場規模 ・世界の疼痛管理市場規模：用途別 - 神経因性疼痛における市場規模 - がん性疼痛における市場規模 - 顔面疼痛・片頭痛における市場規模 - 筋骨格痛における市場規模 ・世界の疼痛管理市場規模：地域別 - 北米の疼痛管理市場規模 アメリカの疼痛管理市場規模 カナダの疼痛管理市場規模 メキシコの疼痛管理市場規模 … - ヨーロッパの疼痛管理市場規模 イギリスの疼痛管理市場規模 フランスの疼痛管理市場規模 ドイツの疼痛管理市場規模 … - アジア太平洋の疼痛管理市場規模 中国の疼痛管理市場規模 インドの疼痛管理市場規模 日本の疼痛管理市場規模 … - 南米/中東の疼痛管理市場規模 ブラジルの疼痛管理市場規模 アルゼンチンの疼痛管理市場規模 南アフリカの疼痛管理市場規模 … - その他地域の疼痛管理市場規模 ・競争状況 ・市場機会・将来の動向 |
The pain management market is valued at USD 79,448.93 million in the current year, and it is projected to be worth USD 120,781.07 million during the forecast period, registering a CAGR of 7.39%.
The COVID-19 pandemic has impacted healthcare systems across the world. Health agencies were involved in containing coronavirus transmission through lockdown norms, and most elective and non-urgent surgeries were postponed globally. As per the Indian Journal of Anaesthesia 2020, COVID-19 negatively impacted pain clinics, including interventional pain management procedures. The Indian Society of Anaesthesiologists also published guidelines on anesthesia and intensive care practices. Also, the Journal of Pain Medicine suggested that epidural nonsteroid injections for radicular pain can be considered in patients who are already immunosuppressed and at high risk of SARS-CoV-2 infection and complications. As per the April 2022 data published by PubMed, it was observed that people across the United States and Canada suffering from chronic pain witnessed a significant increase in pain during the pandemic. However, following the pandemic, effective pain management is practiced among people suffering from chronic pain, as restrictions on non-essential hospital visits are lifted. Hence, it is observed that the current market has reached a pre-pandemic nature.
The well-established business of using painkiller medications as the first line of treatment has significantly contributed to the growth of the pain management market. However, in recent years, the growing reliance on their long-term use, as well as a better understanding of their side effects, has led to an increase in the use of device-based pain management therapies. Post-operative pain is one of the most common. The cost of monitoring and treating adverse effects creates a significant demand for pain management drugs and devices.
The current market is gradually adopting more non-opioid medications to suppress the addiction to opioids and other well-established painkillers on the market. Several non-opioid drugs with mechanisms of action are currently in the early and late stages of development. The regulatory authorities in multiple countries are shifting to alternative approaches, thus fast-tracking those drugs to market approval. The shift is expected to be gradual. Thus, pain management has desirable growth prospects during the forecast period.
The increasing aging population globally is expected to drive the market’s growth, as the prevalence of chronic pain is relatively high among the geriatric population and is considered an independent risk factor for mortality. The increasing number of product launches is also expected to drive the market. For instance, in Octover 2021, Esteve Pharmaceuticals received approval from the US FDA for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Thus, due to such factors, the pain management market is expected to grow significantly over the forecast period.
However, high procedural and purchase costs of pain management devices can restrain the market’s growth.
Pain Management Market Trends
Facial Pain and Migraine Segment is Expected to Exhibit a Significant Growth Rate During the Forecast Period
Headache and facial pain are the few frequent complaints in the emergency and outpatient setting. Most patients who present themselves with headaches have one of the following three main headache syndromes: migraine, cluster headache, or tension headache.
The Migraine Research Foundation updated in 2021 that migraine is an extraordinarily prevalent neurological disease, affecting about 39 million men, women, and children in the United States and 1 billion worldwide. Migraine is considered the third-most prevalent illness in the world. According to the Cleveland Clinic update in 2021, migraine is also the sixth-most disabling illness in the world. For every 10 seconds, someone in the United States goes to the emergency room complaining of a headache, and approximately 1.2 million visits are for acute migraine attacks. Hence, the high prevalence of migraine is expected to propel the growth of the pain management market in the coming years.
Furthermore, the burden of headaches and migraine is found to be the same across the world, and every day, the percentage of people suffering from migraine/headaches increases. For instance, according to the article published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, the high prevalence of migraine is expected to boost the migraine therapeutics market. Moreover, several companies are launching new products in the market, leading to the growth of the segment studied. In February 2022, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. Hence, such new launches and high prevalence of pain, the segment is expected to witness a strong growth in coming years.
In addition, the increasing burden of cancer is also contributing largely to facial pain and headache which is a fueling factor for the segment growth.
North America Captured the Largest Market Share and is Expected to Retain its Dominance During the Forecast Period
North America holds the largest share of the pain management market, with the United States being the most significant contributor to its revenue. Factors such as increasing demand for long-term pain management from the geriatric population and developments in the pain management field are expected to boost the market growth in North America.
Moreover, according to PubMed data from 2022, the prevalence of chronic pain in Americans is increasing. Every year, one out of five people suffers from chronic pain in the region. Since it is one of the most common chronic conditions in the United States, there is a growing demand for pain management across the country. Furthermore, according to the recommendations provided by the American Society of Regional Anesthesia and Pain Medicine (ASRA), chronic opioid therapy and the use of steroids in interventional pain procedures may induce immune suppression, which is very critical as it minimizes the chances of fighting several viral infections. Hence, all the aforesaid factors are expected to increase the demand for pain management devices and drugs over the forecast period.
Overall, the US pain management market is considered highly competitive, primarily due to the significant presence of pain specialist physicians, the increasing trend of product approvals from the FDA, and the robust infrastructure for providing pain management services to patients. For instance, in November 2021, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. formed a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT in the United States and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. Thus, the market is expected to grow significantly in North America over the forecast period.
Pain Management Market Competitor Analysis
The pain management market is highly competitive and consists of several major players. The existing players in the pain management market employ strong competitive strategies, leading to intense competition. Some of the key players in the market are Abbott Laboratories, Johnson & Johnson, Baxter International Inc. (Avante Health Solutions), Becton, Dickinson and Company, and Boston Scientific Corporation, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Long-term Pain Management from the Geriatric Population
4.2.2 Proven Efficacy of Pain Management Devices for the Treatment of Chronic Pain
4.2.3 Development of Novel Pain Management Devices and Techniques
4.3 Market Restraints
4.3.1 Lack of Awareness About the Availability and Use of Pain Management Devices
4.3.2 High Procedural and Purchase Cost of Pain Management Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 BY Mode of Pain Management
5.1.1 Drugs
5.1.1.1 Opioids
5.1.1.2 Non-narcotic Analgesics
5.1.1.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.1.2.2 Anesthetics
5.1.1.2.3 Anticonvulsants
5.1.1.2.4 Anti-depressants
5.1.1.2.5 Other Non-narcotic Analgesics
5.1.2 Devices
5.1.2.1 Neurostimulation Devices
5.1.2.1.1 Transcutaneous Electrical Nerve Stimulation (TENS) Devices
5.1.2.1.2 Brain and Spinal Cord Stimulation (SCS) Devices
5.1.2.2 Analgesic Infusion Pumps
5.1.2.2.1 Intrathecal Infusion Pumps
5.1.2.2.2 External Infusion Pumps
5.2 By Application
5.2.1 Neuropathic Pain
5.2.2 Cancer Pain
5.2.3 Facial Pain and Migraine
5.2.4 Musculoskeletal Pain
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Baxter International Inc. (Avante Health Solutions)
6.1.3 Becton, Dickinson and Company
6.1.4 Boston Scientific Corporation
6.1.5 Fresenius SE & Co. KGaA
6.1.6 Johnson & Johnson
6.1.7 Medtronic PLC
6.1.8 Novartis AG
6.1.9 Endo International PLC
6.1.10 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS